{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"3.6","value":"2.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"PFS is defined as the duration of time from start of treatment to time of progression, death, or completion of the 1-year follow-up, whichever occurs first.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the longest diameter of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO\n\nVorinostat: Given PO","id":"OG000","title":"Arm I (Capecitabine, Vorinostat)"}],"paramType":"MEDIAN","populationDescription":"16 of 25 patients were evaluable for response.","reportingStatus":"POSTED","timeFrame":"From time of treatment initiation to disease progression, death, or completion of the 1 year follow-up, whichever occurs first.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}